Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
專家展望：英特格拉生命科學的八位分析師眼中的展望
Integra Lifesciences (NASDAQ:IART) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Integra Lifesciences（納斯達克：IART）在上個季度接受了8位分析師的分析，揭示了從看好到看淡的各種觀點。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天內情緒的變化，並將它們與前幾個月進行比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target of $28.86.
資產回報率（ROA）：公司的ROA表現突出，超過了行業平均水平。公司令人印象深刻的ROA爲-0.3%，展示了對資產的有效利用。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。